Oracle said last week that it plans to open a new data center in Brazil in August as part of its commitment to help Latin American companies embrace cloud computing.
The new facility will be located in Campinas, São Paulo, and will support growing demand for Oracle’s comprehensive cloud portfolio. The data center was designed to help customers embrace Oracle Cloud Software as a Service (SaaS) applications that have social, mobile and analytic capabilities to help customers deliver services to customers.
“This new data center in Brazil signals our commitment to helping companies in Latin America fully embrace cloud computing, modernize their business and become the leaders in their industry,” Oracle CEO Mark Hurd said. “This is great news for our customers throughout Latin America who are ready to capitalize on the region’s growing economy and take advantage of the unlimited possibilities cloud computing offers.”
Oracle Cloud supports more than 33 billion transactions worldwide daily. The new data center in Latin America brings Oracle’s computing footprint to 19 data centers worldwide. Having a data center in Brazil will enable Oracle to better manage the service-level objectives and data governance for customers throughout Latin America.
The system environment at the data center in Brazil was built using Oracle Engineered Systems to provide customers with high performance and secure cloud services.
Organizations in this Story
- New Colombia Resources says Sannabis test was successful
- Grupo Exito aims to help support Colombia
- Codelco CEO calls for transparency, focus on production goals
- BCP offers tips on choosing master's degree program
- General Tire launches new tire for Andean market
- Latin America talks of boosting pork production, exports @CorferiasBogota
- AIR Worldwide team takes part in wind-engineering conference
- El Salvador's Asesuisa discusses risk management, strategic direction with stakeholders
- Grupo Exito buying lettuce locally to support resocialization program
- Endo selling Mexico-based Grupo-Farmaceutico Somar